Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.46 |
| ▸ | MTOR | P42345 | 9/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114958 | 0.83 | PIK3CA (0.41) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16914051 | 0.83 | PIK3C3 (0.47) | PIK3CAPIK3C3ALDH1A1MEN1KMT2A | |
| SCHEMBL17858704 | 0.83 | PIK3CA (0.47) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL458986 | 0.82 | PIK3CA (0.60) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL114903 | 0.81 | PIK3CA (0.52) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1543605 | 0.80 | PIK3CA (0.52) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3114091 | 0.79 | PIK3CG (0.43) | PIK3CAPIK3CDPIK3CBPIK3CGALDH1A1 | |
| SCHEMBL19736689 | 0.79 | PIK3CA (0.45) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL19728978 | 0.79 | PIK3CA (0.45) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16913931 | 0.79 | PIK3C3 (0.52) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10538533-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-01-21 | — | — | US | disclosed |
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | US | disclosed |
| US-9802960-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802960-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9751854-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751854-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820665-B2 | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment | AMGEN INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2231661-A1 | INHIBITORS OF PI3 KINASE | Amgen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010108074-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010108074-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2009155121-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009085230-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163489-A1 | Inhibitors of PI3 kinase | AMGEN INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118762-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3CA 1261/4885MTOR 2025/4885PIK3CD 628/4885 |
| US-10538533-B2 | Heteroaryls and uses thereof | VPS35, VPS4B, VPS26B | PIK3CA 1261/4885MTOR 2025/4885PIK3CD 628/4885 |
| US-20090163489-A1 | Inhibitors of PI3 kinase | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885MTOR 28/4885PIK3CD 2/4885 |
| US-20150225422-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3CA 1261/4885MTOR 2025/4885PIK3CD 628/4885 |
| US-20170073326-A1 | HETEROARYLS AND USES THEREOF | VPS35, VPS4B, VPS26B | PIK3CA 1261/4885MTOR 2025/4885PIK3CD 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.